GlassScriptPhysician profile
Samyukta Chava
NPI 1467622779
$1,285.77
in general payments reported to CMS, 2019-2025
13 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $190 · 2021: $218 · 2022: $32.12 · 2023: $148 · 2024: $60.41 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $322.13 | 2019-2023 | Sutab, Suflave |
| Abbvie INC. | $279.56 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.90 | 2019-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $113.54 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $100.75 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $81.95 | 2020-2023 | Epclusa |
| Ironwood Pharmaceuticals, INC | $67.02 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.73 | 2019-2021 | |
| Janssen Biotech, INC. | $22.09 | 2025 | Tremfya |
| Redhill Biopharma INC. | $19.87 | 2020 | |
| Daiichi Sankyo INC. | $16.58 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.20 | 2023 | Andexxa |
| Allergan, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samyukta Chava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.